Leerink Partners Initiates Coverage on Senti Biosciences (NASDAQ:SNTI)

Investment analysts at Leerink Partners initiated coverage on shares of Senti Biosciences (NASDAQ:SNTI) in a research note issued to investors on Friday, MarketBeat.com reports. The firm set an “outperform” rating and a $6.00 price target on the stock. Leerink Partners’ target price points to a potential upside of 209.28% from the stock’s previous close.

Several other brokerages have also recently weighed in on SNTI. HC Wainwright started coverage on shares of Senti Biosciences in a research note on Tuesday, October 14th. They issued a “buy” rating and a $12.00 price objective for the company. Chardan Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Senti Biosciences in a research report on Friday, August 8th. Wall Street Zen cut Senti Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $8.75.

Senti Biosciences Trading Up 7.2%

NASDAQ:SNTI opened at $1.94 on Friday. The stock has a 50 day simple moving average of $1.77 and a 200 day simple moving average of $2.07. The stock has a market cap of $51.00 million, a P/E ratio of -0.58 and a beta of 2.09. Senti Biosciences has a 1-year low of $1.26 and a 1-year high of $16.94.

Senti Biosciences (NASDAQ:SNTI) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.10). As a group, sell-side analysts forecast that Senti Biosciences will post -14.54 EPS for the current year.

Hedge Funds Weigh In On Senti Biosciences

A number of institutional investors have recently modified their holdings of SNTI. Heights Capital Management Inc. acquired a new stake in Senti Biosciences in the first quarter valued at about $2,520,000. Citadel Advisors LLC acquired a new position in Senti Biosciences during the third quarter worth about $117,000. Armistice Capital LLC bought a new position in shares of Senti Biosciences in the second quarter worth about $1,883,000. Geode Capital Management LLC boosted its stake in shares of Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares in the last quarter. Finally, Nantahala Capital Management LLC bought a new stake in shares of Senti Biosciences during the 1st quarter valued at approximately $2,984,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.